|
Synonyms: B2036-PEG | Somavert®
pegvisomant is an approved drug (FDA (2003), EMA (2008))
Compound class:
Peptide or derivative
Comment: Pegvisomant is a PEGylated 191 amino acid protein analogue of growth hormone, with antagonist action at the growth hormone receptor. The peptide sequence can be obtained via the ChEMBL link. PEGylation protects the peptide from proteolytic breakdown and extends its bioactive half-life.
|
Classification  |
|
| Compound class | Peptide or derivative |
| Approved drug? | Yes (FDA (2003), EMA (2008)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 7941 | pegvisomant |
| Synonyms |
| B2036-PEG | Somavert® |
| Database Links |
|
| ChEMBL Ligand | CHEMBL1201515 |
| DrugBank Ligand | DB00082 |
| GtoPdb PubChem SID | 187051788 |
| Search PubMed clinical trials | pegvisomant |
| Search PubMed titles | pegvisomant |
| Search PubMed titles/abstracts | pegvisomant |
| Wikipedia | Pegvisomant |
